Process measures reported for ICH patients at HASU1 and HASU2 between 1 October 2016 and 30 March 2018
| HASU1 | HASU2 | |||||
| Before implementation (n=76) | Implementation (n=107) | P value | Before implementation (n=29) | Implementation (n=94) | P value | |
| Anticoagulant reversal | 14/17 (82.4%) | 23/23 (100%) | 0.137 | 2/3 (66.7%) | 24/25 (96.0%) | 0.498 |
| Door-to-needle time (min) | 132 (117–342) | 76 (64–113.5) | 0.006 | 185.5 (183.2–187.8) | 127.5 (74.8–216.3) | 0.336 |
| Intravenous antihypertensive (n, number eligible, % of eligible) | 24/29 (82.8%) | 34/40 (85%) | 1.00 | 4/10 (40.0%) | 25/31 (80.6%) | 0.04 |
| Door-to-target time (min) | 345 (204–866) | 84 (60–117) | <0.001 | 278 (225–333) | 425 (225–901) | 0.358 |
| Needle-to-target time (min) | 243 (139–537) | 37 (21–65) | <0.001 | 270 (210–290) | 269 (109–879) | 0.867 |
| Mean SBP 0–72 hours (mm Hg) | 144.3 (137.3–157.4) | 148.3 (134.1–158.3) | 0.682 | 153.3 (131.1–162.6) | 146.2 (133.9–160.6) | 0.805 |
| SD of SBP 0–72 hours (mm Hg) | 17.7 (12.7–23.2) | 17.8 (13.5–22.0) | 0.858 | 19.1 (11.9–23.1) | 18.2 (13.2–26.9) | 0.770 |
| Neurosurgery; (n, referrals made when indicated, % of eligible) | 24/27 (88.9%) | 41/46 (89.1%) | 1.00 | 10/10 (100%) | 26/30 (86.7%) | 0.543 |
| Neurosurgery; (n, referrals made when not indicated, % of not eligible) | 45/47 (95.7%) | 47/61 (77%) | 0.015 | 15/15 (100%) | 47/63 (74.6%) | 0.067 |
| Neurosurgery; (n, transferred, % of referrals) | 3/69 (4.3%) | 4/88 (4.5%) | 1.00 | 2/26 (7.7%) | 3/74 (4.1%) | 0.834 |
| High dependency unit; n (%) | 0 (0%) | 0 (0%) | NA | 0 (0%) | 0 (0%) | NA |
| Intensive care unit; n (%) | 0 (0%) | 1 (0.9%) | 1.00 | 0 (0%) | 0 (0%) | NA |
| Do-not-resuscitate order<24 hours; n (%) | 17 (22.4%) | 24 (22.4%) | 1.00 | 5 (17.2%) | 18 (19.1%) | 1.00 |
HASU, hyperacute stroke unit; ICH, intracerebral haemorrhage; SBP, systolic blood pressure.